News
06-16-2010, 12:20 AM
The June edition of the Journal of Thoracic Oncology features a study aimed at determining the optimal dose of the chemotherapy drug nab-paclitaxel with carboplatin as a first-line therapy in patients with non-small cell lung cancer. Results will provide researchers with a data needed to guide a phase 3 trial.
More... (http://www.news-medical.net/news/20100616/Study-aims-at-determining-optimal-dose-of-nab-paclitaxel-with-carboplatin-as-first-line-therapy-for-NSCLC.aspx)
More... (http://www.news-medical.net/news/20100616/Study-aims-at-determining-optimal-dose-of-nab-paclitaxel-with-carboplatin-as-first-line-therapy-for-NSCLC.aspx)